thalidomide has been researched along with Atherogenesis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apremilast is a new anti-inflammatory drug that possesses a potential anti-atherosclerosis effect." | 5.72 | Protective roles of apremilast via Sirtuin 1 in atherosclerosis. ( Sui, D; Yu, H, 2022) |
| "Apremilast is a new anti-inflammatory drug that possesses a potential anti-atherosclerosis effect." | 1.72 | Protective roles of apremilast via Sirtuin 1 in atherosclerosis. ( Sui, D; Yu, H, 2022) |
| "Attenuated inflammation and pathological angiogenesis achieved in hypercholesterolemia by thalidomide are accompanied by restoration of renovascular endothelial function but decreased basal renal hemodynamics." | 1.34 | Role of renal cortical neovascularization in experimental hypercholesterolemia. ( Chade, AR; Galili, O; Krier, JD; Lerman, A; Lerman, LO, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sui, D | 1 |
| Yu, H | 1 |
| Kampschulte, M | 1 |
| Gunkel, I | 1 |
| Stieger, P | 1 |
| Sedding, DG | 1 |
| Brinkmann, A | 1 |
| Ritman, EL | 1 |
| Krombach, GA | 1 |
| Langheinrich, AC | 1 |
| Ismail, B | 1 |
| Aboul-Fotouh, S | 1 |
| Mansour, AA | 1 |
| Shehata, HH | 1 |
| Salman, MI | 1 |
| Ibrahim, EA | 1 |
| Hassan, OA | 1 |
| Abdel-tawab, AM | 1 |
| Chade, AR | 1 |
| Krier, JD | 1 |
| Galili, O | 1 |
| Lerman, A | 1 |
| Lerman, LO | 1 |
4 other studies available for thalidomide and Atherogenesis
| Article | Year |
|---|---|
Protective roles of apremilast via Sirtuin 1 in atherosclerosis.
Topics: Atherosclerosis; Cholesterol; Humans; Scavenger Receptors, Class E; Sirtuin 1; Thalidomide | 2022 |
Thalidomide influences atherogenesis in aortas of ApoE(-/-)/LDLR (-/-) double knockout mice: a nano-CT study.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Aortic Diseases; Aortography; Apolipoproteins E; Atheroscle | 2014 |
Behavioural, metabolic, and endothelial effects of the TNF-α suppressor thalidomide on rats subjected to chronic mild stress and fed an atherogenic diet.
Topics: Animals; Antidepressive Agents, Tricyclic; Aorta, Thoracic; Atherosclerosis; Chronic Disease; Depres | 2014 |
Role of renal cortical neovascularization in experimental hypercholesterolemia.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Blood Pressure; Cell Proliferation; Disease Model | 2007 |